Home » Stocks » BridgeBio Pharma

BridgeBio Pharma, Inc. (BBIO)

Stock Price: $39.53 USD -1.44 (-3.51%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 4.84B
Revenue (ttm) 40.56M
Net Income (ttm) -346.32M
Shares Out 122.54M
EPS (ttm) -4.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 19, 2020
Last Price $39.53
Previous Close $40.97
Change ($) -1.44
Change (%) -3.51%
Day's Open 41.26
Day's Range 38.75 - 41.49
Day's Volume 779,754
52-Week Range 14.23 - 48.36

More Stats

Market Cap 4.84B
Enterprise Value 4.48B
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 122.54M
Float 74.20M
EPS (basic) -2.94
EPS (diluted) -4.73
FCF / Share -2.61
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 10.64M
Short Ratio 14.12
Short % of Float 14.35%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 119.43
PB Ratio 18.89
Revenue 40.56M
Operating Income -360.22M
Net Income -346.32M
Free Cash Flow -304.77M
Net Cash 361.64M
Net Cash / Share 2.95
Gross Margin 93.84%
Operating Margin -888.13%
Profit Margin -853.90%
FCF Margin -751.41%
ROA -36.59%
ROE -145.59%
ROIC -66.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (9)

Buy 7
Overweight 1
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(18.34% upside)
Current: $39.53
Target: 46.78
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit38.06--
Operating Income-266-184-43.86
Net Income-261-131-30.57
Shares Outstanding10561.7730.60
Earnings Per Share-2.48-2.12-1.00
Operating Cash Flow-254-137-40.49
Capital Expenditures-2.64-2.18-0.46
Free Cash Flow-256-139-40.95
Cash & Equivalents54643692.00
Total Debt91.7954.51-
Net Cash / Debt45438292.00
Book Value408315-61.43
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name BridgeBio Pharma, Inc.
Country United States
Employees 328
CEO Neil Kumar

Stock Information

Ticker Symbol BBIO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: BBIO
IPO Date June 27, 2019


BridgeBio Pharma engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 20 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, an oral small molecule transthyretin (TTR), which is ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and achondroplasia; BBP-631, a preclinical adeno-associated virus gene transfer product candidate for the treatment of congenital adrenal hyperplasia caused by 21OHD; and BBP-454, a preclinical development program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license agreements with the Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc.; and strategic collaboration agreements with Johns Hopkins University and University of Florida. The company was founded in 2015 and is headquartered in Palo Alto, California.